Patent Number | Patentee Code | S(Subject) | A(Action) | O(Object) |
---|---|---|---|---|
JP2006199666 | AAKS-C; NAGS-C |
Agent | Treats | Amnesia |
JP2008214245 | NAGS-C | Inhibitors | Treats | Alzheimer's Disease |
Inhibitors | Treats | Arteriosclerosis | ||
Inhibitors | Treats | Diabetic Nephropathy | ||
Inhibitors | Treats | Diabetic Neuropathies | ||
Inhibitors | Treats | Diabetic Retinopathy | ||
Inhibitors | Treats | Inflammation | ||
Inhibitors | Treats | Cerebrovascular accident | ||
Inhibitors | Treats | Myocardial Ischemia | ||
WO200294259; EP1387678-A1; AU2002314036; US2004235813 | PLAC-C | Peptides | Disrupts | Adenosine triphosphatase activity |
Amyloid | Interacts_With | aapp | ||
HSP90 Heat-Shock Proteins | Interacts_With | aapp | ||
Pharmaceutical Preparations | Treats | Disease | ||
HSP90 Heat-Shock Proteins | Treats | Disease | ||
HSP90 Heat-Shock Proteins | Treats | Creutzfeldt-Jakob Syndrome | ||
WO200288108; US2003013712; EP1383759; US6727364; AU2002305226; JP2004528351; CN1505625; AU2002305226 | PROC-C | Macular degeneration | Affects | Hair growth |
Pterygium | Affects | Hair growth | ||
Disease | Associated_With | cytokine activity | ||
Acquired Immunodeficiency Syndrome | Causes | Cachexia | ||
Prophylactic treatment | Causes | skin disorder | ||
Prophylactic treatment | Causes | Dermatitis, Atopic | ||
Prophylactic treatment | Causes | Scleroderma | ||
Prophylactic treatment | Causes | Epidermolysis Bullosa | ||
Prophylactic treatment | Causes | Psoriasis | ||
Macular degeneration | Affects | Hair growth | ||
…… | …… | …… | …… | …… |
… | … | … | |||||
---|---|---|---|---|---|---|---|
Acetic Acid-TREATS-CNS Disorder; | |||||||
… | … | … | … | … | … | … | … |
Down Syndrome-Causes-Alzheimer's Disease; Down Syndrome-Causes-Alzheimer's Disease; | Down Syndrome-Causes-Epilepsy; | ||||||
Antibodies-Treats-Alzheimer's Disease; Antibodies-Treats-Neurodegenerative Disorders; | |||||||
Ethanol-Treats-Autoimmune Diseases; Ethanol-Treats-Autoimmune Diseases; | … | Gamma-Aminobutyric Acid-Treats-Alzheimer's Disease; Gamma-Aminobutyric Acid-Treats-Parkinson Disease; Gamma-Aminobutyric Acid-Treats-Neurodegenerative Disorders; Gamma-Aminobutyric Acid-Treats-Alzheimer's Disease; Gamma-Aminobutyric Acid-Treats-Parkinson Disease; Gamma-Aminobutyric Acid-Treats-Neurodegenerative Disorders; Gamma-Aminobutyric Acid-Treats-Neurodegenerative Disorders; Potassium Channel Blockers-Treats-Alzheimer's Disease; Ethanol-Treats-Huntington Disease; Ethanol-Treats-Dementia; Ethanol-Treats-Huntington Disease; Ethanol-Treats-Dementia; Ethanol-Treats-Mental Disorders; Serine-Prevents-Dementia; | Gamma-Aminobutyric Acid-Treats-Cns Disorder; Gamma-Aminobutyric Acid-Treats-Cns Disorder; Ethanol-Treats-Epilepsy; Ethanol-Treats-Cerebrovascular Accident; Ethanol-Treats-Epilepsy; Ethanol-Treats-Cerebrovascular Accident; | … | … | ||
… | … | … | … | … | … | … | … |
Attribute 1 | Attribute 2 | Attribute 3 | |||||
---|---|---|---|---|---|---|---|
Level 1 | Level 2 | Level 1 | Level 2 | Level 1 | Level 2 | ||
Attribute 1 | Level 1 | ||||||
Level 2 | |||||||
Attribute 2 | Level 1 | ||||||
Level 2 | |||||||
Attribute 3 | Level 1 | ||||||
Level 2 |
AAKS-C | ABBI-C | ABBO-C | ABLY-C | ACAD-C | ACET-C | ACIM-C | ACOR-C | ACVE-C | ADCE-C | ADDE-C | ADIR-C | AFFI-C | ….. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AAKS-C | 0 | 0.0897 | 0.1091 | 0.0769 | 0.0684 | 0.1047 | 0.0576 | 0.0538 | 0.0544 | 0.0692 | 0.0682 | 0.0333 | 0.0612 | ….. |
ABBI-C | 0.0712 | 0 | 0.124 | 0.0687 | 0.0681 | 0.126 | 0.0619 | 0.0561 | 0.0511 | 0.0727 | 0.0803 | 0.03 | 0.0686 | ….. |
ABBO-C | 0.0818 | 0.1135 | 0 | 0.0745 | 0.0741 | 0.1288 | 0.0594 | 0.059 | 0.0719 | 0.0867 | 0.0696 | 0.0478 | 0.0548 | ….. |
ABLY-C | 0.0983 | 0.1077 | 0.1242 | 0 | 0.0783 | 0.1336 | 0.0725 | 0.0749 | 0.0765 | 0.0941 | 0.074 | 0.0436 | 0.0715 | ….. |
ACAD-C | 0.1367 | 0.153 | 0.1695 | 0.1251 | 0 | 0.1458 | 0.1009 | 0.0924 | 0.1132 | 0.1395 | 0.1232 | 0.0777 | 0.1038 | ….. |
ACET-C | 0.1058 | 0.1456 | 0.1636 | 0.1174 | 0.0859 | 0 | 0.0954 | 0.0695 | 0.0996 | 0.1131 | 0.0936 | 0.0764 | 0.1006 | ….. |
ACIM-C | 0.1005 | 0.1222 | 0.1306 | 0.0932 | 0.0765 | 0.1318 | 0 | 0.0808 | 0.0812 | 0.1006 | 0.0662 | 0.0408 | 0.0576 | ….. |
ACOR-C | 0.1093 | 0.1296 | 0.1449 | 0.1077 | 0.0781 | 0.1174 | 0.0927 | 0 | 0.09 | 0.1061 | 0.0905 | 0.0708 | 0.0902 | ….. |
ACVE-C | 0.0864 | 0.1028 | 0.1326 | 0.088 | 0.0775 | 0.1312 | 0.0714 | 0.0682 | 0 | 0.0805 | 0.0771 | 0.0425 | 0.0662 | ….. |
ADCE-C | 0.0831 | 0.1041 | 0.1292 | 0.0857 | 0.0857 | 0.1246 | 0.071 | 0.0636 | 0.0605 | 0 | 0.0685 | 0.0518 | 0.0723 | ….. |
ADDE-C | 0.1183 | 0.1464 | 0.1478 | 0.1027 | 0.105 | 0.1391 | 0.0745 | 0.0863 | 0.0941 | 0.1067 | 0 | 0.063 | 0.0788 | ….. |
ADIR-C | 0.1149 | 0.1274 | 0.1561 | 0.1039 | 0.0929 | 0.1556 | 0.0798 | 0.0969 | 0.0908 | 0.1183 | 0.0918 | 0 | 0.0904 | ….. |
AFFI-C | 0.1107 | 0.1342 | 0.133 | 0.0997 | 0.0898 | 0.1463 | 0.0653 | 0.0871 | 0.0828 | 0.1088 | 0.0763 | 0.0583 | 0 | ….. |
AGEN-C | 0.1147 | 0.1321 | 0.1695 | 0.1249 | 0.1017 | 0.1295 | 0.0966 | 0.0826 | 0.0896 | 0.1013 | 0.1174 | 0.0812 | 0.1081 | ….. |
AICU-C | 0.0916 | 0.1114 | 0.1296 | 0.0934 | 0.0862 | 0.1333 | 0.0652 | 0.0741 | 0.0585 | 0.0768 | 0.0689 | 0.0425 | 0.0641 | ….. |
AISS-C | 0.1211 | 0.1379 | 0.1665 | 0.1327 | 0.0944 | 0.159 | 0.1033 | 0.1076 | 0.1065 | 0.1188 | 0.1129 | 0.0764 | 0.0965 | ….. |
AJIN-C | 0.1206 | 0.1338 | 0.1498 | 0.108 | 0.1054 | 0.1572 | 0.0947 | 0.097 | 0.0859 | 0.102 | 0.0913 | 0.0578 | 0.0849 | ….. |
ALKP-C | 0.1511 | 0.1663 | 0.1826 | 0.1467 | 0.1155 | 0.1668 | 0.129 | 0.1101 | 0.1203 | 0.1473 | 0.1285 | 0.0936 | 0.1178 | ….. |
ALKU-C | 0.1144 | 0.1455 | 0.1328 | 0.1083 | 0.0915 | 0.1319 | 0.0975 | 0.0833 | 0.106 | 0.1266 | 0.1094 | 0.0681 | 0.1024 | ….. |
ALLR-C | 0.1419 | 0.1666 | 0.1766 | 0.1337 | 0.0935 | 0.1461 | 0.1179 | 0.0996 | 0.1217 | 0.1443 | 0.1116 | 0.0944 | 0.1089 | ….. |
….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. |
Institutions | rankings based on SAO | rankings based on expert | absolute value | Institutions | rankings based on IPC | rankings based on expert | absolute value |
---|---|---|---|---|---|---|---|
HOFF-C | 1 | 6 | 5 | UYMI-C | 1 | 7 | 6 |
PFIZ-C | 2 | 1 | 1 | UYXM-C | 2 | 9 | 7 |
TAKE-C | 3 | 8 | 5 | UCNT-C | 3 | 8 | 5 |
FARB-C | 4 | 5 | 1 | SYTO-C | 4 | 5 | 1 |
GLAX-C | 5 | 2 | 3 | UJIN-C | 5 | 10 | 5 |
BRIM-C | 6 | 4 | 2 | ZYMO-C | 6 | 2 | 4 |
ASTR-C | 7 | 3 | 4 | UYSY-C | 7 | 4 | 3 |
AMHP-C | 8 | 9 | 1 | ZHJA-C | 8 | 6 | 2 |
SMIK-C | 9 | 10 | 1 | TAKI-C | 9 | 1 | 8 |
NOVS-C | 10 | 7 | 3 | THRE-C | 10 | 3 | 7 |
The sum of absolute value of difference between the rankings based on technology similarity method with rankings based on expert | 26 | 48 | |||||
The average value of absolute value of difference between the rankings based on technology similarity method with rankings based on expert | 2.6 | 4.8 |
No | S | No | S | No | S | No | S | ….. |
---|---|---|---|---|---|---|---|---|
1 | Abetalipoproteinemia | 29 | Alkaline Phosphatase | 67 | Antiepileptic Agents | 112 | Bile Acids | ….. |
2 | Spontaneous abortion | 30 | Alleles | 68 | Epitopes | 113 | Binding Sites | ….. |
3 | Abscess | 31 | Allergens | 69 | Antigens | 114 | Biogenesis | ….. |
4 | Acetic Acid | 32 | Allergic rhinitis NOS | 70 | Antihypertensive Agents | 115 | Biological Products | ….. |
5 | Acetylation | 33 | Alopecia | 71 | Antimalarials | 116 | Biotin | ….. |
6 | Acetylcholine | 34 | Alopecia Areata | 72 | Antineoplastic Agents | 117 | Bipolar Disorder | ….. |
7 | Acetylcholinesterase | 35 | Altitude Sickness | 73 | Antioxidants | 118 | Malignant neoplasm of urinary bladder | ….. |
8 | Acids | 36 | Alzheimer's Disease | 74 | Antiviral Agents | 119 | Bladder, Neurogenic | ….. |
9 | Acquired Immunodeficiency Syndrome | 37 | Amenorrhea | 75 | Anxiety Disorders | 120 | Bulla | ….. |
10 | Acriflavine | 38 | Amides | 76 | Aortic Aneurysm | 121 | Blood Coagulation Disorders | ….. |
11 | Actins | 39 | Amidines | 77 | Aphasia | 122 | Blood Glucose | ….. |
12 | Addison's disease | 40 | Amines | 78 | Apolipoproteins | 123 | Bone Diseases | ….. |
13 | Adenine | 41 | Amino Acids | 79 | Apolipoprotein E | 124 | Bone Diseases, Metabolic | ….. |
14 | adenoma | 42 | Transaminases | 80 | Desire for food | 125 | Bone Marrow Transplantation | ….. |
15 | Adenosine Monophosphate | 43 | Amnesia | 81 | Appetite Regulation | 126 | Bone Regeneration | ….. |
16 | Receptors, Purinergic P1 | 44 | Amyloid | 82 | cardiac arrhythmia | 127 | Bone Resorption | ….. |
17 | ATP phosphohydrolase | 45 | Amyloidosis | 83 | Art Therapy | 128 | Brain Diseases | ….. |
18 | ADENYLATE KINASE | 46 | Amyotrophic Lateral Sclerosis | 84 | Arthritis | 129 | Brain Neoplasms | ….. |
19 | Immunologic Adjuvants | 47 | Analgesics | 85 | Arthritis, Gouty | 130 | Malignant neoplasm of breast | ….. |
….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. |
AAKS-C | ABBI-C | ABBO-C | ABLY-C | ACAD-C | ACET-C | ACIM-C | ACOR-C | ACVE-C | ADCE-C | ADDE-C | ADIR-C | AFFI-C | ….. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AAKS-C | 0 | 0.002 | 0.0016 | 0.0023 | 0.0021 | 0.0023 | 0.0023 | 0.0023 | 0.0023 | 0.0023 | 0.0023 | 0.0023 | 0.0023 | ….. |
ABBI-C | 0.0535 | 0 | 0.0201 | 0.0529 | 0.0509 | 0.0509 | 0.0504 | 0.0513 | 0.0527 | 0.0521 | 0.0511 | 0.0534 | 0.0528 | ….. |
ABBO-C | 0.0656 | 0.0332 | 0 | 0.0653 | 0.0634 | 0.0626 | 0.063 | 0.0642 | 0.0654 | 0.0647 | 0.0637 | 0.066 | 0.0652 | ….. |
ABLY-C | 0.005 | 0.0041 | 0.0041 | 0 | 0.0051 | 0.0049 | 0.005 | 0.005 | 0.0048 | 0.005 | 0.0049 | 0.0048 | 0.005 | ….. |
ACAD-C | 0.0096 | 0.0068 | 0.0068 | 0.0098 | 0 | 0.0086 | 0.0087 | 0.0088 | 0.0096 | 0.0093 | 0.0093 | 0.0096 | 0.0093 | ….. |
ACET-C | 0.0125 | 0.0095 | 0.0087 | 0.0124 | 0.0113 | 0 | 0.0122 | 0.0116 | 0.0123 | 0.0119 | 0.0121 | 0.0125 | 0.0121 | ….. |
ACIM-C | 0.0085 | 0.0049 | 0.005 | 0.0085 | 0.0074 | 0.0082 | 0 | 0.0076 | 0.0079 | 0.0077 | 0.008 | 0.0084 | 0.0075 | ….. |
ACOR-C | 0.0071 | 0.0046 | 0.005 | 0.0071 | 0.0061 | 0.0062 | 0.0063 | 0 | 0.0066 | 0.0062 | 0.0066 | 0.0071 | 0.007 | ….. |
ACVE-C | 0.0023 | 0.0012 | 0.0014 | 0.0021 | 0.0021 | 0.0021 | 0.0018 | 0.0017 | 0 | 0.0019 | 0.0021 | 0.0019 | 0.0021 | ….. |
ADCE-C | 0.004 | 0.0023 | 0.0025 | 0.0041 | 0.0035 | 0.0035 | 0.0033 | 0.0031 | 0.0037 | 0 | 0.0039 | 0.004 | 0.0039 | ….. |
ADDE-C | 0.0091 | 0.0063 | 0.0062 | 0.0089 | 0.0085 | 0.0086 | 0.0085 | 0.0085 | 0.0089 | 0.0089 | 0 | 0.009 | 0.0089 | ….. |
ADIR-C | 0.0016 | 0.0012 | 0.0014 | 0.0014 | 0.0014 | 0.0015 | 0.0015 | 0.0015 | 0.0012 | 0.0015 | 0.0015 | 0 | 0.0015 | ….. |
AFFI-C | 0.0023 | 0.0013 | 0.0013 | 0.0023 | 0.0018 | 0.002 | 0.0014 | 0.0022 | 0.0021 | 0.0021 | 0.0021 | 0.0023 | 0 | ….. |
AGEN-C | 0.0017 | 0.0008 | 0.0013 | 0.0017 | 0.0016 | 0.0018 | 0.0012 | 0.0014 | 0.0015 | 0.0017 | 0.0014 | 0.0017 | 0.0014 | ….. |
AICU-C | 0.0025 | 0.0021 | 0.0013 | 0.0025 | 0.0022 | 0.0023 | 0.0022 | 0.0021 | 0.0021 | 0.0021 | 0.0025 | 0.0025 | 0.0023 | ….. |
AISS-C | 0.006 | 0.0046 | 0.0043 | 0.006 | 0.0051 | 0.0055 | 0.0053 | 0.0056 | 0.0058 | 0.0056 | 0.006 | 0.0058 | 0.0058 | ….. |
AJIN-C | 0.0029 | 0.0023 | 0.0027 | 0.0029 | 0.0025 | 0.0026 | 0.0027 | 0.0027 | 0.0027 | 0.0027 | 0.0027 | 0.0029 | 0.0027 | ….. |
ALKP-C | 0.0027 | 0.0018 | 0.0016 | 0.0027 | 0.0028 | 0.0025 | 0.0027 | 0.0025 | 0.0025 | 0.0025 | 0.0021 | 0.0027 | 0.0027 | ….. |
ALKU-C | 0.0042 | 0.0028 | 0.0025 | 0.0044 | 0.0035 | 0.0039 | 0.0044 | 0.0044 | 0.0044 | 0.0044 | 0.0043 | 0.0042 | 0.0042 | ….. |
ALLR-C | 0.0327 | 0.0297 | 0.0284 | 0.033 | 0.0316 | 0.0311 | 0.0323 | 0.0321 | 0.0327 | 0.0322 | 0.0314 | 0.033 | 0.0327 | ….. |
ALLX-C | 0.0004 | 0.0002 | 0.0002 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | 0.0004 | ….. |
….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. |
AO1 | AO2 | similarity | AO1 | AO2 | similarity | AO1 | AO2 | similarity | AO1 | AO2 | similarity | AO1 | AO2 | similarity | AO1 | AO2 | similarity | ….. |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7 | 661 | 1 | 3 | 4 | 0.5 | 15 | 2,715 | 0.1861 | 15 | 2,285 | 0.079 | 15 | 6,404 | 0.0278 | 107 | 3,714 | 0.0085 | ….. |
28 | 728 | 1 | 3 | 5 | 0.5 | 15 | 7,638 | 0.1861 | 15 | 3,700 | 0.079 | 15 | 7,392 | 0.0278 | 107 | 3,925 | 0.0085 | ….. |
100 | 320 | 1 | 9 | 2,835 | 0.48 | 40 | 1,630 | 0.1828 | 15 | 3,791 | 0.079 | 15 | 7,497 | 0.0278 | 107 | 6,199 | 0.0085 | ….. |
9 | 19 | 0.98 | 9 | 3,872 | 0.48 | 40 | 2,578 | 0.1828 | 15 | 4,099 | 0.079 | 15 | 7,982 | 0.0278 | 107 | 7,552 | 0.0085 | ….. |
86 | 210 | 0.9728 | 9 | 5,795 | 0.48 | 40 | 3,761 | 0.1828 | 15 | 4,295 | 0.079 | 15 | 8,291 | 0.0278 | 27 | 7,813 | 0.0077 | ….. |
46 | 125 | 0.9706 | 90 | 3,053 | 0.4706 | 40 | 3,983 | 0.1828 | 15 | 5,800 | 0.079 | 22 | 1,452 | 0.0278 | 71 | 1,540 | 0.0075 | ….. |
90 | 282 | 0.9706 | 90 | 8,578 | 0.4706 | 40 | 6,052 | 0.1828 | 15 | 5,913 | 0.079 | 22 | 2,325 | 0.0278 | 71 | 3,655 | 0.0075 | ….. |
25 | 835 | 0.96 | 25 | 2,509 | 0.46 | 40 | 7,427 | 0.1828 | 15 | 5,953 | 0.079 | 22 | 3,738 | 0.0278 | 71 | 3,737 | 0.0075 | ….. |
59 | 810 | 0.9445 | 25 | 8,307 | 0.46 | 1 | 3,954 | 0.1667 | 15 | 5,955 | 0.079 | 22 | 3,879 | 0.0278 | 71 | 6,001 | 0.0075 | ….. |
60 | 1,207 | 0.9 | 59 | 2,358 | 0.4445 | 1 | 7,175 | 0.1667 | 15 | 6,056 | 0.079 | 22 | 5,939 | 0.0278 | 71 | 6,129 | 0.0075 | ….. |
87 | 566 | 0.8936 | 59 | 5,968 | 0.4445 | 41 | 1,408 | 0.1667 | 15 | 7,359 | 0.079 | 22 | 6,051 | 0.0278 | 71 | 7,454 | 0.0075 | ….. |
26 | 859 | 0.8846 | 59 | 6,323 | 0.4445 | 41 | 2,662 | 0.1667 | 15 | 7,572 | 0.079 | 22 | 7,369 | 0.0278 | 46 | 1,645 | 0.0073 | ….. |
13 | 41 | 0.875 | 59 | 7,905 | 0.4445 | 41 | 7,606 | 0.1667 | 109 | 3,226 | 0.0715 | 37 | 1,497 | 0.0266 | 46 | 4,009 | 0.0073 | ….. |
27 | 1,137 | 0.8334 | 61 | 3,502 | 0.4385 | 23 | 1,450 | 0.1539 | 69 | 2,962 | 0.0709 | 37 | 3,544 | 0.0266 | 30 | 1,761 | 0.0067 | ….. |
76 | 896 | 0.7756 | 73 | 1,625 | 0.4 | 23 | 2,567 | 0.1539 | 69 | 7,469 | 0.0709 | 37 | 3,736 | 0.0266 | 30 | 2,752 | 0.0067 | ….. |
69 | 258 | 0.775 | 73 | 2,488 | 0.4 | 23 | 2,851 | 0.1539 | 97 | 5,964 | 0.0648 | 37 | 5,920 | 0.0266 | 30 | 4,207 | 0.0067 | ….. |
19 | 66 | 0.7728 | 73 | 6,196 | 0.4 | 23 | 6,274 | 0.1539 | 26 | 1,761 | 0.0633 | 37 | 6,059 | 0.0266 | 30 | 7,587 | 0.0067 | ….. |
74 | 775 | 0.7586 | 73 | 7,854 | 0.4 | 23 | 8,562 | 0.1539 | 26 | 2,752 | 0.0633 | 37 | 7,592 | 0.0266 | 48 | 1,653 | 0.0062 | ….. |
87 | 498 | 0.74 | 87 | 1,592 | 0.3936 | 15 | 1,496 | 0.1464 | 26 | 4,207 | 0.0633 | 41 | 1,340 | 0.0266 | 86 | 4,115 | 0.006 | ….. |
31 | 540 | 0.7364 | 87 | 2,976 | 0.3936 | 15 | 2,353 | 0.1464 | 26 | 7,587 | 0.0633 | 41 | 2,286 | 0.0266 | 23 | 1,536 | 0.0058 | ….. |
….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. |
Number | Cleaning process | Results |
---|---|---|
#1 | Separation of primitive natural semantic relations. | 306,957 |
#2 | Delete 684 records with missing relationships. | 305,913 |
Delete 2231 records with missing subject. | 303,682 | |
Delete 2072 records with missing predicate. | 301,610 | |
Delete 362 records with missing PMID number. | 301,248 | |
#3 | Delete the remarks and analysis information of subject, predicate and object. | 301,248 |
#4 | Delete records where Subject and Object are meaningless numbers and mathematical formulas. | 301,242 |
#5 | Remove the SAO semantic structure that is not related to technology and only retain SAO semantic structure whose semantic relationship are the functionally related and conceptually related. | 122,769 |
……… | ||||
---|---|---|---|---|
……… | ||||
Search strategy | Result |
---|---|
TS=((Alzheimer* (disease* or dementia)) or Alzheimer or (Alzheimer (Dementia* or (Sclerosis or Syndrome) or (Type Dementia) or (Alzheimer Type Senile Dementia))) or (Dementia ((Alzheimer's type) or Alzheimer* or (of The Alzheimer* Type) or (Alzheimer's type) or (in Alzheimer's disease) or (of Alzheimers Type))) or (Primary Senile Degenerative Dementia) or (Senile Dementia of The Alzheimer Type)or (Senile Dementia)or (simple senile dementia)) AND PY=(2000–2018) | 48,268 |
NO | A | O | NO | A | O | NO | A | O | ….. |
---|---|---|---|---|---|---|---|---|---|
1 | Affects | Myelination | 21 | Affects | Hair Growth | 41 | Affects | Tauopathies | ….. |
2 | Affects | Septicemia | 22 | Affects | AIDS Dementia Complex | 42 | Affects | Graves’ Disease | ….. |
3 | Affects | Chronic Pain | 23 | Affects | Rheumatoid Arthritis | 43 | Affects | Orchitis | ….. |
4 | Affects | Bacteria | 24 | Affects | Diabetes Mellitus | 44 | Affects | Hashimoto Disease | ….. |
5 | Affects | Helper-Inducer T-Lymphocyte | 25 | Affects | Glomerulonephritis | 45 | Affects | Autoimmune Oophoritis | ….. |
6 | Affects | Proteins | 26 | Affects | Spinal Muscular Atrophy | 46 | Affects | Oxidation-Reduction | ….. |
7 | Affects | Gngm | 27 | Affects | Parkinson Disease | 47 | Affects | Prostate | ….. |
8 | Affects | Response | 28 | Affects | Psoriasis | 48 | Affects | Gluconeogenesis | ….. |
9 | Affects | Aging-Related Process | 29 | Affects | Cerebellar Degeneration | 49 | Affects | Drug Interactions | ….. |
10 | Affects | Entire Nervous System | 30 | Affects | Amyotrophic Lateral Sclerosis | 50 | Affects | Acidification | ….. |
11 | Affects | Neuraxis | 31 | Affects | Lupus Erythematosus, Systemic | 51 | Affects | Energy Balance | ….. |
12 | Affects | Hydrolysis | 32 | Affects | Retinitis Pigmentosa | 52 | Affects | Graft Rejection | ….. |
13 | Affects | Alzheimer's Disease | 33 | Affects | Retroviridae Infections | 53 | Affects | Facilitation | ….. |
14 | Affects | Disease | 34 | Affects | Inflammatory Disorder | 54 | Affects | Receptor Function | ….. |
15 | Affects | Dementia | 35 | Affects | Patients | 55 | Affects | Autoimmune Diseases | ….. |
16 | Affects | Signal Transduction Inhibition | 36 | Affects | Immune System Diseases | 56 | Affects | Sex Behavior | ….. |
17 | Affects | Folliculitis | 37 | Affects | Neurodegenerative Disorders | 57 | Affects | Growth | ….. |
18 | Affects | Diabetes | 38 | Affects | Neoplasm | 58 | Affects | Organism | ….. |
19 | Affects | Aging | 39 | Affects | Lamellipodium Biogenesis | 59 | Affects | Memory Disorders | ….. |
20 | Affects | Apoptosis | 40 | Affects | Intestinal Diseases | 60 | Affects | Insulin Resistance | ….. |
….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. | ….. |